Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical
Avanos Medical (NYSE:AVNS) has announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical (CMM), a private company in Raleigh, NC. The divested portfolio includes TriVisc® and GenVisc® 850 injection products for osteoarthritis knee pain treatment.
The strategic move aligns with Avanos' transformation strategy to focus on its core segments in Pain Management & Recovery and Specialty Nutrition Systems. The ownership transfer is effective immediately, with Avanos providing transition support through the end of 2025 to ensure continuity of service.
Avanos Medical (NYSE:AVNS) ha annunciato la cessione della sua linea di prodotti a base di Acido Ialuronico (HA) a Channel-Markers Medical (CMM), un'azienda privata con sede a Raleigh, NC. Il portafoglio ceduto include i prodotti iniettabili TriVisc® e GenVisc® 850 per il trattamento del dolore al ginocchio causato dall'osteoartrite.
Questa mossa strategica è in linea con la strategia di trasformazione di Avanos, che mira a concentrarsi sui suoi segmenti principali di Gestione del Dolore e Recupero e Sistemi di Nutrizione Speciale. Il trasferimento di proprietà è effettivo immediatamente, con Avanos che fornirà supporto durante la transizione fino alla fine del 2025 per garantire la continuità del servizio.
Avanos Medical (NYSE:AVNS) ha anunciado la venta de su línea de productos de Ácido Hialurónico (HA) a Channel-Markers Medical (CMM), una empresa privada ubicada en Raleigh, NC. El portafolio vendido incluye los productos inyectables TriVisc® y GenVisc® 850 para el tratamiento del dolor de rodilla por osteoartritis.
Esta decisión estratégica se alinea con la estrategia de transformación de Avanos, enfocándose en sus segmentos principales de Manejo del Dolor y Recuperación y Sistemas de Nutrición Especializada. La transferencia de propiedad es efectiva de inmediato, y Avanos brindará apoyo durante la transición hasta finales de 2025 para asegurar la continuidad del servicio.
Avanos Medical (NYSE:AVNS)는 노스캐롤라이나 주 롤리에 위치한 비상장 회사인 Channel-Markers Medical (CMM)에 히알루론산(HA) 제품 라인을 매각했다고 발표했습니다. 매각된 포트폴리오에는 골관절염 무릎 통증 치료용 주사제인 TriVisc® 및 GenVisc® 850이 포함되어 있습니다.
이번 전략적 조치는 Avanos가 통증 관리 및 회복, 전문 영양 시스템의 핵심 부문에 집중하는 변혁 전략과 부합합니다. 소유권 이전은 즉시 효력이 발생하며, Avanos는 2025년 말까지 원활한 서비스 연속성을 위해 전환 지원을 제공할 예정입니다.
Avanos Medical (NYSE:AVNS) a annoncé la cession de sa gamme de produits à base d'acide hyaluronique (HA) à Channel-Markers Medical (CMM), une entreprise privée basée à Raleigh, NC. Le portefeuille cédé comprend les produits injectables TriVisc® et GenVisc® 850 destinés au traitement de la douleur au genou liée à l'arthrose.
Cette décision stratégique s'inscrit dans la stratégie de transformation d'Avanos, qui vise à se concentrer sur ses segments clés de gestion de la douleur et récupération ainsi que systèmes de nutrition spécialisée. Le transfert de propriété est effectif immédiatement, Avanos assurant un soutien pendant la transition jusqu'à fin 2025 pour garantir la continuité du service.
Avanos Medical (NYSE:AVNS) hat den Verkauf seiner Hyaluronsäure-(HA)-Produktlinie an Channel-Markers Medical (CMM), ein privates Unternehmen in Raleigh, NC, bekannt gegeben. Das veräußerte Portfolio umfasst die Injektionsprodukte TriVisc® und GenVisc® 850 zur Behandlung von Knieschmerzen bei Osteoarthritis.
Dieser strategische Schritt steht im Einklang mit Avanos' Transformationsstrategie, sich auf die Kernsegmente Schmerzmanagement & Erholung sowie Spezialernährungssysteme zu konzentrieren. Der Eigentumsübergang ist sofort wirksam, wobei Avanos bis Ende 2025 Übergangsunterstützung zur Sicherstellung der Servicekontinuität bietet.
- Strategic alignment with core business focus on Pain Management & Recovery and Specialty Nutrition Systems
- Streamlined product portfolio allowing for more focused investment in strategic priorities
- Transition support through 2025 ensures business continuity
- Loss of revenue stream from HA product line
- Reduction in product portfolio diversity
Insights
Avanos' divestiture of HA products sharpens focus on core segments while potentially improving resource allocation and profitability.
Avanos Medical's divestiture of its Hyaluronic Acid (HA) product line represents a strategic portfolio realignment aimed at concentrating resources on its two core business segments: Pain Management & Recovery and Specialty Nutrition Systems. By selling off the TriVisc® and GenVisc® 850 injection products, which treat osteoarthritis pain in the knee, Avanos is executing a focused growth strategy that could strengthen its competitive position in its primary markets.
This transaction follows a common healthcare industry pattern where companies divest non-core assets to sharpen strategic focus. For Avanos, this move likely serves multiple purposes: it streamlines operations, potentially improves capital allocation efficiency, and may enhance profit margins if the divested products were underperforming relative to the core portfolio. The agreement to provide transition support through the end of 2025 suggests a thoughtful approach to maintaining business continuity and customer relationships.
For Channel-Markers Medical, this acquisition meaningfully expands their presence in the musculoskeletal health and injectable pain therapy markets. The HA products complement CMM's existing portfolio in joint health and regenerative therapies, potentially creating synergies and enhanced market positioning.
While financial terms weren't disclosed, this transaction should be evaluated as part of Avanos' broader transformation strategy. The divestiture's success will ultimately depend on how effectively Avanos redeploys resources toward innovation and growth in its strategic segments, potentially improving long-term shareholder value through a more focused approach.
This transaction aligns with Avanos' ongoing transformation, which is focused on advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems.
The divested portfolio includes the TriVisc® and GenVisc® 850 injection products, which are indicated for the treatment of osteoarthritis (OA) pain in the knee. These injectable HA therapies are designed to help patients manage OA symptoms and improve joint function.
"This divestiture represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focused growth," said Dave Pacitti, Avanos' chief executive officer. "By aligning our product portfolio more closely with our strategic priorities, we expect to strengthen our ability to invest in those areas where we see the greatest potential to lead, innovate, and deliver long-term value for patients, customers, and shareholders."
Channel-Markers Medical specializes in the development and commercialization of joint health, regenerative therapies, and minimally invasive pain management solutions. The acquisition of the HA portfolio supports CMM's strategic goal to expand its presence in musculoskeletal health and injectable pain therapies.
With today's announcement, ownership of Avanos' HA product line has officially transferred to CMM. Avanos will provide transition support through the end of 2025 to ensure uninterrupted service and support for customers, partners, and patients.
"This acquisition aligns with our mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life," said David Toledo, one of CMM's managing partners. "We're proud to integrate these trusted brands into our portfolio as we accelerate our growth in the pain therapy market."
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
About Channel-Markers Medical
Channel-Markers Medical is a privately held medical device company specializing in the development and commercialization of joint health, regenerative therapies, and minimally invasive pain management solutions. With a commitment to innovation, patient access, and outcomes, the company serves healthcare providers and patients across the Orthopaedic, Sports Medicine, and Pain Management specialties. Learn more at: www.channel-markers.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-announces-divestiture-of-hyaluronic-acid-product-line-to-channel-markers-medical-302518890.html
SOURCE Avanos Medical
FAQ
What products did Avanos Medical (AVNS) divest to Channel-Markers Medical?
Why did Avanos Medical (AVNS) sell its HA product line?
How long will Avanos Medical provide transition support after the HA product line sale?
Who is Channel-Markers Medical, the buyer of Avanos' HA products?
What is the strategic importance of this acquisition for Channel-Markers Medical?
